Novozymes Biopharma wins Technology Innovation award for half-life extension platform

02-03-2012: Novozymes Biopharma, part of Novozymes A/S, announced it has received the 2012 Drug Delivery Partnerships™ (DDP) Technology Innovation award for the company’s half-life extension platform. The albumin based technology platform offers the potential to enhance patient quality of life through tailoring drug circulatory half-life to meet specific medical needs.  The DDP awards acknowledge success within the drug delivery industry and were selected by peers from the pharmaceutical industry at the 16th annual DDP conference, held in Las Vegas, Nevada, January 2012. The award was collected by Dr Darrell Sleep, Head of Research and Development, UK.

“Novozymes is delighted to have won the DDP technology innovation award” says Dave Mead, Business Development Director, Novozymes Biopharma. “The albumin based technology is adaptable and can be used for both genetic fusion (Albufuse® Flex) or conjugation (Recombumin® Flex), providing a unique ability to decrease or increase a drug’s half-life. Clearly this will help manufacturers to develop pharmaceuticals with enhanced pharmacokinetic properties, offering more favorable dosing regimes and improving patient compliance, while reducing healthcare costs. For the solution to be recognized as the most exciting delivery technology of the past year, at one of the pharmaceutical industry’s largest drug delivery conferences, is a real testament to its potential importance to the market."